Avner Schlessinger

9.9k total citations · 3 hit papers
110 papers, 6.0k citations indexed

About

Avner Schlessinger is a scholar working on Molecular Biology, Biochemistry and Oncology. According to data from OpenAlex, Avner Schlessinger has authored 110 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Molecular Biology, 32 papers in Biochemistry and 27 papers in Oncology. Recurrent topics in Avner Schlessinger's work include Amino Acid Enzymes and Metabolism (32 papers), Drug Transport and Resistance Mechanisms (23 papers) and Protein Structure and Dynamics (19 papers). Avner Schlessinger is often cited by papers focused on Amino Acid Enzymes and Metabolism (32 papers), Drug Transport and Resistance Mechanisms (23 papers) and Protein Structure and Dynamics (19 papers). Avner Schlessinger collaborates with scholars based in United States, United Kingdom and France. Avner Schlessinger's co-authors include Burkhard Rost, Andrej Săli, Peter M.U. Ung, Kathleen M. Giacomini, Claire Colas, Marco Punta, Guy Yachdav, Hao Fan, John J. Irwin and Thomas E. Ferrin and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Avner Schlessinger

104 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ModBase, a database of annotated comparative protein structure models, and associated resources

2010 672 citations Ursula Pieper, Avner Schlessinger et al. profile →
PredictProtein—an open resource for online prediction of protein structural and functional features

2014 455 citations Marco Punta, Avner Schlessinger et al. profile →
Artificial intelligence and machine learning‐aided drug discovery in central nervous system diseases: State‐of‐the‐arts and future directions

2020 252 citations Avner Schlessinger et al. profile →

Peers

Countries citing papers authored by Avner Schlessinger

Since Specialization

Citations

This map shows the geographic impact of Avner Schlessinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Avner Schlessinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Avner Schlessinger more than expected).

Fields of papers citing papers by Avner Schlessinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Avner Schlessinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Avner Schlessinger. The network helps show where Avner Schlessinger may publish in the future.

Co-authorship network of co-authors of Avner Schlessinger

This figure shows the co-authorship network connecting the top 25 collaborators of Avner Schlessinger. A scholar is included among the top collaborators of Avner Schlessinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Avner Schlessinger. Avner Schlessinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A critical residue mediates proper assembly and gating of GIRK2 channels 2025 ·The Journal of General Physiology ·(unknown), (unknown), (unknown), (unknown), Yulin Zhao, Ian W. Glaaser, Peng Yuan, Avner Schlessinger, Paul A. Slesinger	0
2	Expanding the utility of variant effect predictions with phenotype-specific models 2025 ·Nature Communications ·David Stein, (unknown), (unknown), Matthew Mort, Peter D. Stenson, Jean‐Laurent Casanova, D.N. Cooper, Bertrand Boisson, Peng Zhang, Avner Schlessinger, Yuval Itan	0
3	Development of a genetic priority score to predict drug side effects using human genetic evidence 2025 ·Nature Communications ·Áine Duffy, (unknown), David Stein, Joshua K. Park, Matthew Mort, Marie Verbanck, Avner Schlessinger, Yuval Itan, D.N. Cooper, Daniel M. Jordan, Ghislain Rocheleau, Ron Do	0
4	Development of a human genetics-guided priority score for 19,365 genes and 399 drug indications 2024 ·Nature Genetics ·Áine Duffy, Ben Omega Petrazzini, David Stein, Joshua K. Park, Iain S. Forrest, (unknown), Ha My T. Vy, (unknown), Carla Márquez‐Luna, Matthew Mort, Marie Verbanck, Avner Schlessinger, Yuval Itan, D.N. Cooper, Ghislain Rocheleau, Daniel M. Jordan, Ron Do	11
5	A comprehensive exploration of the druggable conformational space of protein kinases using AI-predicted structures 2024 ·PLoS Computational Biology ·(unknown), Yan Chak Li, David Stein, Gaurav Pandey, Avner Schlessinger	7
6	A web portal for exploring kinase-substrate interactions 2024 ·npj Systems Biology and Applications ·John A. P. Sekar, Yan Chak Li, Avner Schlessinger, Gaurav Pandey	1
7	Functional genomics of OCTN2 variants informs protein-specific variant effect predictor for Carnitine Transporter Deficiency 2022 ·Proceedings of the National Academy of Sciences ·(unknown), Gregory McInnes, Julia E. H. Brown, Neil Thomas, (unknown), Marcus Y. Chin, Antoine Koehl, Michelle R. Arkin, Avner Schlessinger, Renata C. Gallagher, Yun S. Song, Russ B. Altman, Kathleen M. Giacomini	12
8	Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling 2021 ·Cancer Discovery ·Christos Adamopoulos, Tamer A. Ahmed, Maxwell R. Tucker, Peter M.U. Ung, Min Xiao, Zoi Karoulia, Angelo Amabile, Xuewei Wu, Stuart A. Aaronson, Celina Ang, Vito W. Rebecca, Brian D. Brown, Avner Schlessinger, Meenhard Herlyn, Qi Wang, David E. Shaw, Poulikos I. Poulikakos	40
9	Protein structure–based gene expression signatures 2021 ·Proceedings of the National Academy of Sciences ·Rayees Rahman, (unknown), Jens Hansen, Yuguang Xiong, J. G. Coen van Hasselt, Eric A. Sobie, Marc R. Birtwistle, Evren U. Azeloglu, Ravi Iyengar, Avner Schlessinger	5
10	Rational design of ASCT2 inhibitors using an integrated experimental-computational approach 2021 ·Proceedings of the National Academy of Sciences ·(unknown), (unknown), Alisa A. Garaeva, (unknown), (unknown), (unknown), Massimiliano Bonomi, Dirk Jan Slotboom, Cristina Paulino, Christof Grewer, Avner Schlessinger	47
11	Human neurons from Christianson syndrome iPSCs reveal mutation-specific responses to rescue strategies 2021 ·Science Translational Medicine ·Sofia B. Lizarraga, Li Ma, (unknown), Laura I. van Dyck, Qing Wu, Qing Ouyang, Brian C. Kavanaugh, (unknown), Liane L. Livi, Matthew F. Pescosolido, M Schmidt, Shanique Alabi, (unknown), (unknown), Diane Hoffman–Kim, Ece D. Gamsiz Uzun, Avner Schlessinger, Richard N. Jones, Eric M. Morrow	20
12	Transcriptomic profiling of human cardiac cells predicts protein kinase inhibitor-associated cardiotoxicity 2020 ·Nature Communications ·J. G. Coen van Hasselt, Rayees Rahman, Jens Hansen, Alan D. Stern, Jaehee V. Shim, Yuguang Xiong, Amanda J. Pickard, Gomathi Jayaraman, Bin Hu, Milind Mahajan, James M. Gallo, Joseph Goldfarb, Eric A. Sobie, Marc R. Birtwistle, Avner Schlessinger, Evren U. Azeloglu, Ravi Iyengar	28
13	SLC13A3 variants cause acute reversible leukoencephalopathy and α‐ketoglutarate accumulation 2019 ·Annals of Neurology ·Joseph P. Dewulf, Elsa Wiame, Imen Dorboz, Monique Elmaleh, Apolline Imbard, Dana Dumitriu, Malgorzata Rak, Agnès Bourillon, Raphaël Helaers, (unknown), Florence Renaldo, Odile Boespflug‐Tanguy, Marie‐Françoise Vincent, Jean‐François Benoist, Ron A. Wevers, Avner Schlessinger, Emile Van Schaftingen, Marie‐Cécile Nassogne, Manuel Schiff	19
14	Environmental Pressure May Change the Composition Protein Disorder in Prokaryotes 2015 ·PLoS ONE ·Esmeralda Vicedo, Avner Schlessinger, Burkhard Rost	10
15	Co-expression and co-localization of hub proteins and their partners are encoded in protein sequence 2014 ·Molecular BioSystems ·Ariel Feiglin, (unknown), Avner Schlessinger, Burkhard Rost, Yanay Ofran	1
16	Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET 2011 ·Proceedings of the National Academy of Sciences ·Avner Schlessinger, Ethan G. Geier, Hao Fan, John J. Irwin, Brian K. Shoichet, Kathleen M. Giacomini, Andrej Săli	104
17	Protein disorder—a breakthrough invention of evolution? 2011 ·Current Opinion in Structural Biology ·Avner Schlessinger, Christian Schaefer, Esmeralda Vicedo, (unknown), Marco Punta, Burkhard Rost	115
18	Function of human Rh based on structure of RhCG at 2.1 Å 2010 ·Proceedings of the National Academy of Sciences ·Franz Gruswitz, Sarika Chaudhary, Joseph D. Ho, Avner Schlessinger, (unknown), Chi-Min Ho, Andrej Săli, Connie M. Westhoff, Robert M. Stroud	163
19	Comparison of human solute carriers 2010 ·Protein Science ·Avner Schlessinger, Pär Matsson, James E. Shima, Ursula Pieper, Sook Wah Yee, Libusha Kelly, Leonard Apeltsin, Robert M. Stroud, Thomas E. Ferrin, Kathleen M. Giacomini, Andrej Săli	87
20	Automated Identification of Complementarity Determining Regions (CDRs) Reveals Peculiar Characteristics of CDRs and B Cell Epitopes 2008 ·The Journal of Immunology ·Yanay Ofran, Avner Schlessinger, Burkhard Rost	66

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact